MarketCap
Facebook
X
Telegram
BioCardia EV/EBITDA Ratio | BCDA
Annual EV/EBITDA Ratio BioCardia
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.98 | -0.483 | -0.353 | -2.93 | -0.747 | -2.01 | -1.66 | -3.75 | -7.02 | -7.66 | 14.4 | 51.2 | 570 | -8.41 | -13.3 | 729 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 729 K | -13.3 | 45.6 K |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kadmon Holdings, Inc.
KDMN
|
-7.37 | - | - | $ 1.7 B |  USA |
 |
Liminal BioSciences
LMNL
|
-0.811 | - | - | $ 256 M |  Canada |
 |
argenx SE
ARGX
|
38.2 | $ 972.42 | 1.05 % | $ 59.6 B |  Niderland |
 |
XBiotech
XBIT
|
0.841 | $ 1.97 | 3.2 % | $ 60.1 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
-17.5 | - | -2.54 % | $ 57.2 M | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-4.74 | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
0.718 | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
16.1 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-11.2 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
0.897 | $ 1.76 | -2.09 % | $ 2.99 M | USA |
 |
Viridian Therapeutics
VRDN
|
-8.14 | $ 30.86 | 2.22 % | $ 3.14 B | USA |
 |
Translate Bio, Inc.
TBIO
|
350 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-14 | - | - | $ 1.94 B | Canada |
 |
Urovant Sciences Ltd.
UROV
|
-1.91 K | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-47 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-0.823 | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-4.47 | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
44 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-8.58 | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-6.03 | $ 41.4 | 2.35 % | $ 3.28 B | Canada |
 |
Leap Therapeutics
LPTX
|
0.106 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-3.7 | $ 31.45 | 2.08 % | $ 1.62 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
0.407 | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
19.2 | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Cortexyme
CRTX
|
-2.13 | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
24.7 | $ 3.66 | -1.35 % | $ 802 M | Britain |
 |
Daré Bioscience
DARE
|
-1.83 | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
-1.04 | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-19.8 | $ 16.05 | -2.85 % | $ 217 M | USA |
 |
Halozyme Therapeutics
HALO
|
25 | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
-481 | $ 15.34 | 0.1 % | $ 13.2 B | China |
 |
Aptorum Group Limited
APM
|
29.7 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
-2.85 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
-9.31 | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
-3.77 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
-0.888 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
9.61 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-8.98 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
70.6 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
ARCA biopharma
ABIO
|
0.248 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
1.28 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-0.487 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-0.963 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-0.164 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
0.111 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0795 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
1.19 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
52.9 | - | - | $ 5.18 B | USA |